Agios Pharmaceuticals Stock (NASDAQ: AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO) Stock, Quote.Headers.trade-ideas

Agios Pharmaceuticals

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

AGIO

Biotech

Earnings

News

Health Care

Movers

Trading Ideas

General

Agios Pharmaceuticals&#39; Phase 3 ACTIVATE-KidsT study results reveal that mitapivat achieved a 28.1% transfusion reduction in children with PK deficiency compared to 11.8% with placebo. Secondary endpoints show transfusion-free and normal hemoglobin responses in the mitapivat arm only.

Agios Pharmaceuticals&#39; Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides

Istanbul,,Tr,-,January,29,2021:,Novavax,Vaccine.,Syringe,Close

ACLS

HALO

IRTC

LBTYB

LEGN

NEOG

NUVL

NVAX

NVDA

SMAR

TWST

VRNT

Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts.

Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?

Lab.julia koblitz

Agios Pharmaceuticals shares rose after it announced its Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia achieved the primary endpoint of transfusion reduction response.

Why Is Agios Pharmaceuticals Stock Trading Higher On Monday?

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals Inc

AGIOS PHARMACEUTICALS ORD

RBC Capital analyst Gregory Renza reiterates Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Outperform and maintains $55 price target.

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Outperform on Agios Pharmaceuticals, Maintains $55 Price Target

The FDA Granted Orphan Drug Designation To Agios Pharmaceuticals' Tebapivat (AG-946) For Myelodysplastic Syndromes

Agios Pharmaceuticals shares are trading higher after the company announced it will receive $1.1 billion in milestone payments.

– Agios Expects to Receive $905 Million Payment from Royalty Pharma and $200 Million Payment from Servier in Q3 2024; Payments Increase Agios' Pro-Forma Cash Position as of June 30, 2024, to $1.7 Billion – &nbsp;
– Strong Cash Position to Enable Agios to Prepare for Potential PYRUKYND&#xAE; (Mitapivat) Launches in Thalassemia in 2025 and Sickle Cell Disease in 2026 and Drive Pipeline Progress –

Agios To Receive $1.1B Milestone Payments After FDA Approval Of Vorasidenib

RBC Capital analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Outperform and raises the price target from $53 to $55.

RBC Capital Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $55

On Thursday, Agios Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) released topline results from the global Phase 3 ACTIVATE-KidsT study of mitapivat in children aged 1 to &lt;18 years with PK deficiency <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/g40093772/agios-announces-results-from-phase-3-activate-kidst-study-of-mitapivat-in-children-with-pk-deficie" rel="noreferrer noopener">who are regularly transfused</a>.
Pyruvate kinase deficiency is a&nbsp;rare genetic disorder characterized by the premature destruction of red blood cells.
Using Bayesian methodology, the prespecified statistical criterion for the primary endpoint in ACTIVATE-KidsT was not met using low or moderate borrowing of data from the ACTIVATE-T study in adults.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39141375/why-is-agios-pharmaceuticals-stock-trading-higher-on-monday" rel="noreferrer noopener">Why Is Agios Pharmaceuticals Stock Trading Higher On Monday</a>?
In the ACTIVATE-KidsT study, 28.1% of patients in the mitapivat arm achieved the primary endpoint of transfusion reduction response, compared to 11.8% of patients in the placebo arm.
Transfusion-free response and normal hemoglobin response were secondary endpoints in this study and were only observed in patients in the mitapivat arm.
Mitapivat was generally safe and well-tolerated, with safety results consistent with the safety profile for mitapivat previously observed in adults with PK deficiency who are regularly transfused.
Six patients (18.8%) in the mitapivat arm compared to 0 in the placebo arm had a transfusion-free response, defined as no red blood cell transfusions from Week 9 through Week 32 of the double-blind period.
Four patients (12.5%) in the mitapivat arm achieved a normal hemoglobin response compared to 0 in the placebo arm.
Pyrukynd&nbsp;(mitapivat) is a pyruvate kinase activator indicated for hemolytic anemia in adults with pyruvate kinase (PK) deficiency in&nbsp;the&nbsp;U.S. and PK deficiency in adult patients in the&nbsp;European Union.
In addition, Agios has completed enrollment in the ACTIVATE-Kids study of mitapivat in children with PK deficiency who are not regularly transfused and expects to report topline data in 2025.
In the second quarter, the company reported Pyrukynd sales of $8.6 million, up <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/g40093822/agios-reports-business-highlights-and-second-quarter-2024-financial-results" rel="noreferrer noopener">from $6.71 million a year ago</a>, missing the consensus of $9.31 million.&nbsp;
The company reported an EPS loss of $(1.69), up from $(1.51) a year ago and missing the consensus of $(1.60).
Price Action: AGIO stock is down 4.87% at $44.14 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40107403/cignas-q2-profit-beats-analyst-estimates-as-evernorth-health-services-growth-builds-momentum-reiter" target="_blank" rel="noreferrer noopener">Cigna&#8217;s Q2 Profit Beats Analyst Estimates As Evernorth Health Services Growth Builds Momentum, Reiterates Annual Outlook</a>.</li>
</ul>

Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides

Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) reported quarterly losses of $(1.69) per share which missed the analyst consensus estimate of $(1.60) by 5.62 percent. The company reported quarterly sales of $8.615 million which missed the analyst consensus estimate of $9.307 million by 7.44 percent. This is a 28.35 percent increase over sales of $6.712 million the same period last year.

Earnings Misses

Agios Pharmaceuticals Q2 2024 GAAP EPS $(1.69) Misses $(1.60) Estimate, Sales $8.615M Miss $9.307M Estimate

Agios Announces Results From Phase 3 ACTIVATE-KidsT Study Of Mitapivat In Children With PK Deficiency Who Are Regularly Transfused; Says Prespecified Statistical Criterion For Primary Endpoint In ACTIVATE-KidsT Was Not Met

Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $46.25, a high estimate of $53.00, and a low estimate of $33.00. This current average has increased by 30.91% from the previous average price target of $35.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1718632894_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Agios Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tessa Romero</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$53.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$53.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Agios Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Agios Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Agios Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Agios Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AGIO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Agios Pharmaceuticals analyst ratings.</a>
<h2>Discovering Agios Pharmaceuticals: A Closer Look</h2>
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
<h3>Financial Insights: Agios Pharmaceuticals</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Agios Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 46.0%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Agios Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -995.84% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Agios Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -10.49%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -9.13%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.09, Agios Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Agios Pharmaceuticals

Cantor Fitzgerald analyst Eric Schmidt reiterates Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today presented detailed results from the global Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia in a plenary session (abstract #S104) at the European Hematology Association 2024 (EHA2024) Hybrid Congress, which is being held June 13-16, 2024, in Madrid, Spain. In a related poster presentation (abstract #P1529), the company presented additional data from the ENERGIZE study highlighting clinically meaningful improvements in health-related quality of life measures and patient-reported outcomes among patients in the mitapivat arm compared to those in the placebo arm.
The ENERGIZE study achieved its primary endpoint, with mitapivat demonstrating a statistically significant increase in hemoglobin response rate compared to placebo. Statistical significance was also achieved for both key secondary endpoints associated with change from baseline in FACIT-Fatigue Score and hemoglobin concentration. These improvements were observed across all pre-specified subgroups.

Agios Announced Earlier Results From Its  Phase 3 ENERGIZE Study Of Mitapivat In Non-Transfusion-Dependent Thalassemia; Study Achieved Its Primary Endpoint

<a href="https://docs.publicnow.com/viewDoc?hash_primary=94808CEEFD31376A3A6A2796DEEF8050584F174C" title="https://docs.publicnow.com/viewDoc?hash_primary=94808CEEFD31376A3A6A2796DEEF8050584F174C">https://docs.publicnow.com/viewDoc?hash_primary=94808CEEFD31376A3A6A2796DEEF8050584F174C</a>

Agio Pharmaceuticals Announces Poster Titled 'Improvements In Fatigue And 6-minute Walk Test In Adults With Alpha- Or Beta-non–Transfusion-dependent Thalassemia: The Phase 3 Energize Trial Of Mitapivat'

JP Morgan analyst Tessa Romero reinstates Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Neutral and announces $46 price target.

Initiation

JP Morgan Reinstates Neutral on Agios Pharmaceuticals, Announces $46 Price Target

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$130.00</td>
<td>$620.0K</td>
<td>423</td>
<td>1.0K</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$345.00</td>
<td>$203.3K</td>
<td>88</td>
<td>258</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$20.00</td>
<td>$74.8K</td>
<td>12.1K</td>
<td>174</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$70.00</td>
<td>$454.7K</td>
<td>26.7K</td>
<td>162</td>
</tr>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$82.50</td>
<td>$29.0K</td>
<td>1.6K</td>
<td>108</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$25.00</td>
<td>$29.8K</td>
<td>417</td>
<td>89</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$800.00</td>
<td>$31.4K</td>
<td>115</td>
<td>85</td>
</tr>
<tr>
<td>AGIO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$40.00</td>
<td>$39.9K</td>
<td>520</td>
<td>30</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/19/24</td>
<td>$110.00</td>
<td>$25.6K</td>
<td>465</td>
<td>5</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$55.00</td>
<td>$44.0K</td>
<td>72</td>
<td>0</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding A (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>), we observe a put option trade with bearish sentiment. It expires in 36 day(s) on July 19, 2024. Parties traded 2000 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $620.0K, with a price of $310.0 per contract. There were 423 open contracts at this strike prior to today, and today 1041 contract(s) were bought and sold. 
• Regarding ISRG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), we observe a call option sweep with bearish sentiment. It expires in 36 day(s) on July 19, 2024. Parties traded 25 contract(s) at a $345.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $203.3K, with a price of $8115.0 per contract. There were 88 open contracts at this strike prior to today, and today 258 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with bearish sentiment. It expires in 218 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $74.8K, with a price of $748.0 per contract. There were 12168 open contracts at this strike prior to today, and today 174 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bearish sentiment. It expires in 582 day(s) on January 16, 2026. Parties traded 846 contract(s) at a $70.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $454.7K, with a price of $535.0 per contract. There were 26718 open contracts at this strike prior to today, and today 162 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a put option trade that happens to be bullish, expiring in 64 day(s) on August 16, 2024. This event was a transfer of 108 contract(s) at a $82.50 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $269.0 per contract. There were 1615 open contracts at this strike prior to today, and today 108 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be bearish, expiring in 218 day(s) on January 17, 2025. This event was a transfer of 10 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $29.8K, with a price of $2980.0 per contract. There were 417 open contracts at this strike prior to today, and today 89 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option sweep that happens to be bearish, expiring in 155 day(s) on November 15, 2024. This event was a transfer of 11 contract(s) at a $800.00 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $31.4K, with a price of $2860.0 per contract. There were 115 open contracts at this strike prior to today, and today 85 contract(s) were bought and sold. 
• Regarding AGIO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>), we observe a call option trade with bearish sentiment. It expires in 36 day(s) on July 19, 2024. Parties traded 50 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $39.9K, with a price of $799.0 per contract. There were 520 open contracts at this strike prior to today, and today 30 contract(s) were bought and sold. 
• For ILMN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), we notice a call option trade that happens to be neutral, expiring in 36 day(s) on July 19, 2024. This event was a transfer of 45 contract(s) at a $110.00 strike. The total cost received by the writing party (or parties) was $25.6K, with a price of $570.0 per contract. There were 465 open contracts at this strike prior to today, and today 5 contract(s) were bought and sold. 
• Regarding GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we observe a call option trade with bearish sentiment. It expires in 8 day(s) on June 21, 2024. Parties traded 50 contract(s) at a $55.00 strike. The total cost received by the writing party (or parties) was $44.0K, with a price of $880.0 per contract. There were 72 open contracts at this strike prior to today, and today 0 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

GILD

Hims & Hers Health, Inc. Class A Common Stock

HIMS

ILMN

ISRG

VKTX

10 Health Care Stocks Whale Activity In Today's Session

These mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Agios Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) shares soared 29.13% in the last week after reporting that its transfusion-dependent (TD) alpha-or beta-thalassemia study <a href="https://www.benzinga.com//node/39141375">met primary endpoint</a>. Several analysts <a href="https://www.benzinga.com/quote/agio/analyst-ratings">raised their forecasts</a> after the announcement.</li>
<li>Verint Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) shares are zoomed 22.40% after the company on Tuesday reported better-than-expected Q1 financial results <a href="https://www.benzinga.com//node/39170267" target="_blank" rel="noreferrer noopener">and issued strong FY25 guidance</a>.</li>
<li>Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares gained 21.54% in the last week after the U.S. Food and Drug Administration&#8217;s advisory committee voted to recommend <a href="https://www.benzinga.com/general/biotech/24/06/39204978/novavax-stock-rallies-in-pre-market-as-company-plans-to-deliver-covid-19-vaccine-by-september">updated vaccines for JN.1-lineage of COVID-19</a>.</li>
<li>Nuvalent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>) shares rose 20.52%.</li>
<li>Neogen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) shares increased 19.25%.</li>
<li>Twist Bioscience Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) shares jumped 18.40% after Guggenheim initiated coverage on the stock with a Buy rating <a href="https://www.benzinga.com/quote/twst/analyst-ratings" target="_blank" rel="noreferrer noopener">and announced a price target of $53</a>.</li>
<li>Smartsheet Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMAR#NYSE">SMAR</a>) shares escalated 18.01% after the company reported better-than-expected Q1 financial results and announced an<a href="https://www.benzinga.com//node/39195040" target="_blank" rel="noreferrer noopener"> inaugural $150 million share repurchase program</a>. Many analysts changed<a href="https://www.benzinga.com//node/39206468" target="_blank" rel="noreferrer noopener"> their price targets</a>.</li>
<li>Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock grew 14.03%  after the company<a href="https://www.benzinga.com//node/39211537" target="_blank" rel="noreferrer noopener"> raised its FY24 guidance</a>.</li>
<li>Legend Biotech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) <a href="https://www.benzinga.com/quote/legn/analyst-ratings" target="_blank" rel="noreferrer noopener">shares rose 13.93%</a>.</li>
<li>Liberty Global Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBTYB#NASDAQ">LBTYB</a>) shares upped 12.48%.</li>
</ol>
Photo via Shutterstock
Also Read: <a href="https://www.benzinga.com/news/24/06/39243316/gamestop-and-nio-were-among-the-11-biggest-large-cap-losers-last-week-june-1-june-7-are-these-in-you">GameStop And NIO Were Among The 11 Biggest Large Cap Losers Last Week (June 1-June 7): Are These In Your Portfolio?</a>

WIIM

Agios Pharmaceuticals shares are trading higher after RBC Capital maintained an Outperform rating on the stock and raised its price target from $44 to $53. Also, Goldman Sachs maintained a Neutral rating on the stock and raised its price target from $33 to $53.

Goldman Sachs analyst Salveen Richter maintains Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Neutral and raises the price target from $33 to $53.

Goldman Sachs Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $53

RBC Capital analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Outperform and raises the price target from $44 to $53.

RBC Capital Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $53

Shares Agios Pharmaceuticals Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) climbed after it was revealed a Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent (TD) alpha-or beta-thalassemia achieved its primary endpoint of <a href="https://www.benzinga.com/pressreleases/24/06/g39132225/agios-announces-phase-3-energize-t-study-of-mitapivat-met-primary-endpoint-and-all-key-secondary-e" target="_blank" rel="noreferrer noopener">transfusion reduction response</a>.
Statistical significance was also achieved for all key secondary endpoints evaluating additional measures of reduction of transfusion burden compared to placebo.
The 258-patient study met its primary endpoint of transfusion reduction response: TRR, defined as a ≥50% reduction in transfused red blood cell (RBC) units with a reduction of ≥2 units of transfused RBCs in any consecutive 12-week period through Week 48 compared with baseline.
<ul>
<li>Treatment with mitapivat demonstrated a statistically significant reduction in transfusion burden compared to placebo, as measured by the TRR endpoint.</li>
<li>In the mitapivat arm, 30.4% of patients achieved a transfusion reduction response, compared to 12.6% of patients in the placebo arm.</li>
</ul>
Treatment with mitapivat also demonstrated a statistically significant reduction in additional measures of transfusion reduction response compared to placebo.
In addition, a higher proportion of patients in the mitapivat arm (9.9%) than the placebo arm (1.1%) achieved the secondary endpoint of transfusion independence.
Overall, during the 48-week double-blind period, the incidence of adverse events (AEs) was similar across mitapivat and placebo arms.
Based on the safety and efficacy data observed in ENERGIZE-T, the company will proceed with the previously stated plans of U.S. regulatory submission by the end of this year.
The company intends to submit a marketing application for Pyrukynd (mitapivat) in the U.S. by the end of 2024 based on all available data from both studies, <a href="https://www.benzinga.com/general/biotech/24/01/36468800/why-is-blood-disorder-focused-agios-pharmaceuticals-stock-trading-higher-today">including Phase 3 ENERGIZE study</a>.
The company also plans to submit marketing applications in Europe and the Gulf Cooperation Council (GCC) countries.
Price Action: AGIO shares are up 16.87% at $42.47 at last check Monday.
Photo: Julia Koblitz via Unsplash

Agios Pharmaceuticals shares are trading higher after the company reported Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia achieved its primary endpoint of transfusion reduction response.

Agios Pharmaceuticals Q2 2024 Earnings Preview

Agios Pharmaceuticals GAAP EPS of -$1.69 misses by $0.09, revenue of $8.62M misses by $0.69M

TD Cowen analyst Marc Frahm has maintained their bullish stance on AGIO stock, giving a Buy rating on July 23. Marc Frahm has given his Buy rating ...

Buy Rating for Agios Pharma Backed by Promising Mitapivat Trials and Strategic Gulf Expansion

Agios' Pyrukynd misses primary endpoint in phase 3 pediatric rare blood disorder trial

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teladoc (TDOC – Research Report), SAGE Therapeutics (SAGE – Resea...

Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), SAGE Therapeutics (SAGE) and Agios Pharma (AGIO)

Agios to receive $1.1B in milestone payments for vorasidenib approval

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Agios Pharma (AGIO – Research Report) today and set a price target of $56.00. ...

Piper Sandler Sticks to Its Buy Rating for Agios Pharma (AGIO)

Small-cap and mid-cap Health Care has room to rally - Roth MKM

Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agios Pharma (AGIO – Research Report) and Healthequi...

Analysts' Top Healthcare Picks: Agios Pharma (AGIO), Healthequity (HQY)

ABBV

ACHC

ADMA

ANAB

BDTX

BLFS

GEHC

GMED

LGND

MLAB

PODD

PSCH

REGN

SAGE

SUPN

TDOC

Press Releases

Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET

Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Agios Pharmaceuticals

Agios Pharmaceuticals (AGIO) Forecast

Agios Pharmaceuticals (NASDAQ:AGIO) Stock, Quote.Headers.trade-ideas